Allogene Therapeutics (ALLO) Cash from Investing Activities (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Cash from Investing Activities data on file, last reported at -$29.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 579.08% year-over-year to -$29.6 million; the trailing twelve-month figure through Mar 2026 stood at $59.8 million (changed 0.11% YoY), and the FY2025 full-year result was $95.6 million, up 26.25% from the prior year.
• Cash from Investing Activities declined to -$29.6 million in Q1 2026, from $33.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $112.9 million in Q1 2023 to a low of -$76.0 million in Q3 2024.
• A 5-year average of $24.2 million and a median of $24.9 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 604.69% in 2023 and slumped 579.08% in 2026, its largest moves.
• Tracing ALLO's Cash from Investing Activities over 5 years: stood at $49.6 million in 2022, then soared by 36.02% to $67.5 million in 2023, then dropped by 18.57% to $54.9 million in 2024, then sank by 38.81% to $33.6 million in 2025, then tumbled by 188.03% to -$29.6 million in 2026.
• Business Quant data shows ALLO's Cash from Investing Activities at -$29.6 million in Q1 2026, $33.6 million in Q4 2025, and $11.9 million in Q3 2025.